| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/18/2004 | CA2090911C Aqueous pharmaceutical formulations of sodium cromoglycate |
| 05/13/2004 | WO2004040302A1 REGULATION OF INTERACTION BETWEEN RAPL AND Rap1 |
| 05/13/2004 | WO2004040002A2 ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS |
| 05/13/2004 | WO2004039994A1 Sodium chondroitin sulfate, chondroitin sulfate-containing material and processes for producing the same |
| 05/13/2004 | WO2004039972A1 H17t213-transgenic animal, novel h17t213 protein and dna thereof |
| 05/13/2004 | WO2004039869A1 High-molecular weight derivatives of camptothecins |
| 05/13/2004 | WO2004039829A2 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
| 05/13/2004 | WO2004039828A1 Method of obtaining polymorphic form i of finasteride |
| 05/13/2004 | WO2004039823A1 Novel macrolide derivatives havaing effect of potentiating antifungal activity |
| 05/13/2004 | WO2004039817A1 Cardiolipin molecules and method of synthesis |
| 05/13/2004 | WO2004039816A1 Crystal of inorganic acid salt of cephem compound |
| 05/13/2004 | WO2004039809A1 Novel quinoxaline derivatives |
| 05/13/2004 | WO2004039807A1 Pyridopyrrolizine and pyridoindolizine derivatives |
| 05/13/2004 | WO2004039806A1 Heterocyclic compounds |
| 05/13/2004 | WO2004039803A2 Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use |
| 05/13/2004 | WO2004039798A1 Quaternary ammonium compounds and their use as antimuscarinic agents |
| 05/13/2004 | WO2004039794A1 Cell activator, process for producing cell activator and appratus therefor |
| 05/13/2004 | WO2004039782A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| 05/13/2004 | WO2004039774A2 Mitotic kinesin inhibitors |
| 05/13/2004 | WO2004039454A1 Formulations containing melatonin, ginkgo biloba, and biotin |
| 05/13/2004 | WO2004039453A2 7h-dibenzo[b,g][1,5]dioxocin-5-one derivatives and use thereof |
| 05/13/2004 | WO2004039426A2 Transdermal delivery system for water insoluble drugs |
| 05/13/2004 | WO2004039409A2 Composition comprising activators of ik potassium channels and calcineurin antagonists and use thereof |
| 05/13/2004 | WO2004039408A1 Medicinal composition |
| 05/13/2004 | WO2004039407A1 Apoptosis inducer |
| 05/13/2004 | WO2004039405A1 Use of sglt homolog |
| 05/13/2004 | WO2004039404A1 Therapeutic agent for spinal canal stenosis |
| 05/13/2004 | WO2004039403A1 Remedy for corneal failure |
| 05/13/2004 | WO2004039395A1 Immunnoevasive agent for preventing graft rejection |
| 05/13/2004 | WO2004039382A1 Enhanced production of clotting factors by cryoprecipitation |
| 05/13/2004 | WO2004039379A1 Anticancer or antiviral composition |
| 05/13/2004 | WO2004039378A1 Preparations comprising 1,3 and/or 1,6 beta glucans for the treatment of infections and inflammations in animals |
| 05/13/2004 | WO2004039377A1 Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders |
| 05/13/2004 | WO2004039376A1 Use of piperazine derivatives as ccr1 antagonists |
| 05/13/2004 | WO2004039375A1 Methods of using ccr1 antagonists as immunomodulatory agents |
| 05/13/2004 | WO2004039372A1 Medicament component of berberine for the use of prevention and treatment of psycological dependence on and analgesic tolerance to morphine |
| 05/13/2004 | WO2004039371A2 Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain |
| 05/13/2004 | WO2004039369A1 Daily melatonin dosing units |
| 05/13/2004 | WO2004039368A1 Peroral preparation for prevention of or treatment for atopic dermatitis |
| 05/13/2004 | WO2004039367A1 Proline derivatives having affinity for the calcium channel alpha-2-delta subunit |
| 05/13/2004 | WO2004039366A1 Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| 05/13/2004 | WO2004039365A1 Agent for preventing or treating neuropathy |
| 05/13/2004 | WO2004039364A1 Novel use of dioxocin-5-on derivatives |
| 05/13/2004 | WO2004039363A1 Anti-cancer composition comprising dmxaa or related compound |
| 05/13/2004 | WO2004039362A2 Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia |
| 05/13/2004 | WO2004039361A1 Pulsatile release compositions of milnacipran |
| 05/13/2004 | WO2004039360A1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 05/13/2004 | WO2004039359A2 Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders |
| 05/13/2004 | WO2004039358A1 Adhesive composition for dermal patch and production process thereof |
| 05/13/2004 | WO2004039357A1 Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers |
| 05/13/2004 | WO2004039356A1 A method for normalizing insulin levels |
| 05/13/2004 | WO2004039355A1 Therapeutic compositions |
| 05/13/2004 | WO2004039336A2 Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia |
| 05/13/2004 | WO2004039330A2 Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls |
| 05/13/2004 | WO2004039328A2 Fludrocortisone treatment for hearing loss |
| 05/13/2004 | WO2004039327A2 Use of equol for treating androgen mediated diseases |
| 05/13/2004 | WO2004039326A2 Propofol with cysteine |
| 05/13/2004 | WO2004039325A2 Treatment of pain with jnk inhibitors |
| 05/13/2004 | WO2004039322A2 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
| 05/13/2004 | WO2004039321A2 Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease |
| 05/13/2004 | WO2004039320A2 STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF |
| 05/13/2004 | WO2004039317A2 Analogs and prodrugs of buprenorphine |
| 05/13/2004 | WO2004039315A2 Method for treating wounds to promote healing |
| 05/13/2004 | WO2004039313A2 Preventing desensitization of receptors |
| 05/13/2004 | WO2004039311A2 Human vps4a and vps4b functions in viral budding |
| 05/13/2004 | WO2004039308A2 Quinazolinone compositions for regulation of gene expression related to pathological processes |
| 05/13/2004 | WO2004039247A2 Compositions and methods for pain reduction |
| 05/13/2004 | WO2004039238A2 Modulation of zinc levels to improve tissue properties |
| 05/13/2004 | WO2004030623A3 Nitroxide radioprotector formulations and methods of use |
| 05/13/2004 | WO2004024167A3 Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes |
| 05/13/2004 | WO2004024078A3 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 05/13/2004 | WO2004024065A3 Substituted bicyclic thiophene derivatives, compostions containing such compounds and methods of use |
| 05/13/2004 | WO2004022529A3 Diarylurea derivatives and their use as chloride channel blockers |
| 05/13/2004 | WO2004022102A3 Pharmaceutical formulation with non-steroidal antiphlogistic agents and nucleic acids for the internalization of nucleic acids into eucaryotic cells |
| 05/13/2004 | WO2004022074A8 Nutritional compositions comprising a non-glucose carbohydrate or pectin and soluble fiber |
| 05/13/2004 | WO2004019960A3 Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity |
| 05/13/2004 | WO2004017950A3 Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| 05/13/2004 | WO2004017943A3 Non-vesicular cationic lipid formulations |
| 05/13/2004 | WO2004017938A3 Nitrofurantoin controlled release dosage form |
| 05/13/2004 | WO2004014917A3 Antitumoral analogs of lamellarins |
| 05/13/2004 | WO2004014335A3 Dual-spike release formulation for oral drug delivery |
| 05/13/2004 | WO2004014271A9 Protection of the female reproductive system from natural and artificial insults |
| 05/13/2004 | WO2004013101A3 N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy |
| 05/13/2004 | WO2004009542A3 Process for preparing certain pyrrolotriazine compounds |
| 05/13/2004 | WO2004009085A3 Taste masked sumatriptan tablets and processes for their preparation |
| 05/13/2004 | WO2004006931A3 Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
| 05/13/2004 | WO2004005293A3 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 05/13/2004 | WO2004002461A3 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 05/13/2004 | WO2004000293A3 Use of taurine or derivatives thereof for the treatment of alopecia |
| 05/13/2004 | WO2004000045A3 Liquid compositions comprising non-digestible oligosaccharides and green tea catechins, method and uses thereof |
| 05/13/2004 | WO2003106461A3 Pseudopolymorphic forms of a hiv protease inhibitor |
| 05/13/2004 | WO2003103637A3 Modified release, multiple unit drug delivery systems |
| 05/13/2004 | WO2003101389A3 Relief of aids symptoms |
| 05/13/2004 | WO2003097835A3 Pharmaceutical compositions for the treatment of cancer |
| 05/13/2004 | WO2003094888A9 Processes for forming a drug delivery device |
| 05/13/2004 | WO2003092617A3 Combinations for the treatment of inflammatory skin disorders |
| 05/13/2004 | WO2003090684B1 Polymer compositions containing a macrocyclic triene compound |
| 05/13/2004 | WO2003086321A3 Modified release minerals |
| 05/13/2004 | WO2003086302A3 Propagermanium for treating myeloma bone disease and other bone disorders |
| 05/13/2004 | WO2003082207A3 Volume efficient controlled release dosage form |